uniQure (NASDAQ:QURE) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of uniQure (NASDAQ:QURE) from a sell rating to a hold rating in a research note issued to investors on Saturday morning.

QURE has been the topic of a number of other reports. Leerink Partners increased their price target on shares of uniQure from $36.00 to $70.00 and gave the company an “outperform” rating in a research report on Thursday, June 18th. Chardan Capital boosted their price objective on shares of uniQure from $31.00 to $37.00 and gave the company a “buy” rating in a report on Thursday, April 30th. Wells Fargo & Company boosted their price objective on shares of uniQure from $60.00 to $75.00 and gave the company an “overweight” rating in a report on Thursday, July 30th. HC Wainwright upped their target price on shares of uniQure from $50.00 to $80.00 and gave the company a “buy” rating in a research note on Monday, June 29th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of uniQure in a report on Friday, June 26th. Thirteen research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $65.00.

uniQure Stock Up 3.3%

Shares of uniQure stock opened at $48.62 on Friday. The company has a quick ratio of 10.01, a current ratio of 10.01 and a debt-to-equity ratio of 0.15. uniQure has a 12 month low of $8.73 and a 12 month high of $71.50. The business has a fifty day simple moving average of $41.26 and a 200 day simple moving average of $27.86. The stock has a market cap of $3.37 billion, a PE ratio of -12.12 and a beta of 0.92.

uniQure (NASDAQ:QURE) last released its earnings results on Wednesday, July 29th. The biotechnology company reported ($1.22) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.40). uniQure had a negative net margin of 1,350.73% and a negative return on equity of 111.96%. The company had revenue of $5.84 million during the quarter, compared to analyst estimates of $5.45 million. During the same period in the previous year, the company posted ($0.69) EPS. Research analysts predict that uniQure will post -3.74 EPS for the current year.

Insider Transactions at uniQure

In other news, insider Walid Abi-Saab sold 30,000 shares of the business’s stock in a transaction dated Tuesday, June 30th. The stock was sold at an average price of $46.42, for a total value of $1,392,600.00. Following the sale, the insider directly owned 148,235 shares in the company, valued at $6,881,068.70. The trade was a 16.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Madhavan Balachandran sold 11,685 shares of the company’s stock in a transaction dated Wednesday, June 17th. The stock was sold at an average price of $45.06, for a total value of $526,526.10. Following the transaction, the director directly owned 43,254 shares of the company’s stock, valued at $1,949,025.24. This represents a 21.27% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 388,229 shares of company stock worth $16,817,099. Company insiders own 4.65% of the company’s stock.

Institutional Investors Weigh In On uniQure

Several institutional investors have recently bought and sold shares of QURE. Torren Management LLC acquired a new stake in shares of uniQure in the fourth quarter valued at approximately $28,000. IFP Advisors Inc bought a new position in uniQure in the fourth quarter valued at $48,000. Smartleaf Asset Management LLC acquired a new stake in uniQure in the 4th quarter valued at $48,000. CIBC Private Wealth Group LLC acquired a new stake in uniQure in the 3rd quarter valued at $50,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in uniQure by 42.7% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,027 shares of the biotechnology company’s stock worth $72,000 after buying an additional 906 shares in the last quarter. Institutional investors own 78.83% of the company’s stock.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.